Biotech Values

[willyw]

To date, eight of 13 GT1a patients had a RBV dose interruption.1

So far pretty strong efficacy and we can see there are at the very least 13 GT1a's.
This is fairly impressive data since the 3D program is generally more efficacious on GT1b, and so far they are reporting 10/10 SVR-4 in prelim data.

100% SVR-4 is a GREAT success rate, even in ordinary aggregate HCV infected groups.It will be interesting to see the entire study after they all have SVR-12's

It will be interesting to see the data on the interruption protocols. (dose reduction/cessation)